(Q42683864)

English

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

scientific article published on November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin (English)

1 reference

Europe PubMed Central

4 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Matthew C Riddle

1

1 reference

Europe PubMed Central

4 November 2017

Robert R Henry

2

1 reference

Europe PubMed Central

4 November 2017

Terri H Poon

3

1 reference

Europe PubMed Central

4 November 2017

Bei Zhang

4

1 reference

Europe PubMed Central

4 November 2017

Susanna M Mac

5

1 reference

Europe PubMed Central

4 November 2017

John H Holcombe

6

1 reference

Europe PubMed Central

4 November 2017

Dennis D Kim

7

1 reference

Europe PubMed Central

4 November 2017

David G Maggs

8

1 reference

Europe PubMed Central

4 November 2017

publication date

1 November 2006

1 reference

Europe PubMed Central

4 November 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

4 November 2017

22

1 reference

Europe PubMed Central

4 November 2017

6

1 reference

Europe PubMed Central

4 November 2017

483-491

1 reference

Europe PubMed Central

4 November 2017

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapies with insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired effect of sulfonylurea following increased dosage.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.646

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.646

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42683864&oldid=1965535095"